Optic IconOptic Logo
|
SearchCollectionsBenchmarks

Patritumab deruxtecan

Aliases
HER3-DXd, U3-1402

6 clinical trials

1 product

7 abstracts

9 indications

1 target

Indication
Brain Metastases
Indication
Adult
Indication
Breast Cancer Metastatic
Indication
Breast Cancer
Indication
HER2-low breast carcinoma
Indication
Advanced Non-Small Cell Squamous Lung Cancer
Indication
Solid Tumor
Indication
Locally Advanced Breast Cancer
Indication
non-small cell lung cancer
Target
EGFR mutation
Abstract
Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trial.
Org: Med. Univ. of Vienna, Hospital Professor Doutor Fernando Fonseca EPE, Arnau de Vilanova University Hospital,
Abstract
HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors.
Org: Università Milano-Bicocca,
Clinical trial
A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases
Status: Not yet recruiting, Estimated PCD: 2025-01-01
Clinical trial
Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
Status: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
Multicenter, Single-arm, 3 Cohort, Phase II Trial of HER3-DXd in Patients With Active Brain Metastases From Metastatic Breast Cancer and Non-small Cell Lung Cancer, and in Patients With Leptomeningeal Disease From Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase II Study of U3-1402 (Patritumab Deruxtecan) in Patients With Metastatic Breast Cancer
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase 1 Open-Label Study of HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 2 Trial of neoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan (HER3-DXd; U3-1402) With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial
Status: Active (not recruiting), Estimated PCD: 2025-03-31
Abstract
A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).
Org: Sarah Cannon Research Institute/Tennessee Oncology, Daiichi Sankyo Inc., Rutgers Cancer Institue of New Jersey, Highlands Oncology, Washington University School of Medicine,
Abstract
Characterization of diverse targetable alterations in ERBB2 and ERBB3 in 93,465 non-small cell lung cancers (NSCLC).
Org: Memorial Sloan Kettering Cancer Center, Foundation Medicine, Inc., Cambridge, MA, University of California San Diego, Moores Cancer Center,
Abstract
Exploring expression levels of HER2, HER3, MET, Claudin18.2, and MUC16 across 16 cancer types using an artificial intelligence-powered immunohistochemistry analyzer.
Org: Oncology Therapeutic Development, Lunit Inc., Samsung Medical Center, Sungkyunkwan University School of Medicine, Chonnam National University Medical School and Hwasun Hospital,
Abstract
The changes of HER3 expression in head and neck cancer patients treated with induction chemotherapy.
Org: Daiichi Sankyo Co. Ltd., Translational Research Department, Daiichi Sankyo RD Novare Co., Ltd., Daiichi Sankyo RD Novare Co., Ltd.,
Product
HER3-DXd
Abstract
https://www.abstractsonline.com/pp8/#!/10828/presentation/10503